Candel Therapeutics (CADL) Other Non-Current Assets (2020 - 2025)
Candel Therapeutics recorded quarterly Other Non-Current Assets of $416000.0 in Q4 2025, up 38.67% quarter-over-quarter from $300000.0 in Q3 2025, and up 560.32% year-over-year from $63000.0 in Q4 2024.
Candel Therapeutics' Other Non-Current Assets history runs 6 years deep, the most recent figure standing at $416000.0 for Q4 2025.
- In Q4 2025, Other Non-Current Assets rose 560.32% year-over-year to $416000.0; the TTM figure through Dec 2025 stood at $416000.0 (up 560.32% YoY), while the FY2025 annual figure was $416000.0, up 560.32% from the prior year.
- Other Non-Current Assets came in at $416000.0 for Q4 2025 at Candel Therapeutics, up from $300000.0 in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $1.7 million in Q2 2021 to a low of $45000.0 in Q2 2025.
- A 5-year average of $331473.7 and a median of $266000.0 in 2022 frame the typical range for Other Non-Current Assets.
- On a YoY basis, Other Non-Current Assets climbed as much as 560.32% in 2025 and fell as far as 85.0% in 2025.
- Candel Therapeutics' Other Non-Current Assets stood at $400000.0 in 2021, then plunged by 33.5% to $266000.0 in 2022, then increased by 12.78% to $300000.0 in 2023, then slumped by 79.0% to $63000.0 in 2024, then soared by 560.32% to $416000.0 in 2025.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $416000.0, $300000.0, and $45000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 12.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 60,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.26 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.13 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 63.55 Mn |
| 10 | Candel Therapeutics | 449.62 Mn | 449.62 Mn | - | 416,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 416,000.00 |
| Sep 30, 2025 | 300,000.00 |
| Jun 30, 2025 | 45,000.00 |
| Mar 31, 2025 | 58,000.00 |
| Dec 31, 2024 | 63,000.00 |
| Sep 30, 2024 | 75,000.00 |
| Jun 30, 2024 | 300,000.00 |
| Mar 31, 2024 | 266,000.00 |
| Dec 31, 2023 | 300,000.00 |
| Sep 30, 2023 | 139,000.00 |
| Jun 30, 2023 | 300,000.00 |
| Mar 31, 2023 | 266,000.00 |
| Dec 31, 2022 | 266,000.00 |
| Sep 30, 2022 | 266,000.00 |
| Jun 30, 2022 | 266,000.00 |
| Mar 31, 2022 | 437,000.00 |
| Dec 31, 2021 | 400,000.00 |
| Sep 30, 2021 | 423,000.00 |
| Jun 30, 2021 | 1.71 Mn |
| Dec 31, 2020 | 349,000.00 |